BR112015022701A2 - composições e métodos para segmentação de n-acetilglicosamina transferase o-ligada e promoção da cicatrização de feridas. - Google Patents

composições e métodos para segmentação de n-acetilglicosamina transferase o-ligada e promoção da cicatrização de feridas.

Info

Publication number
BR112015022701A2
BR112015022701A2 BR112015022701A BR112015022701A BR112015022701A2 BR 112015022701 A2 BR112015022701 A2 BR 112015022701A2 BR 112015022701 A BR112015022701 A BR 112015022701A BR 112015022701 A BR112015022701 A BR 112015022701A BR 112015022701 A2 BR112015022701 A2 BR 112015022701A2
Authority
BR
Brazil
Prior art keywords
segmentation
promotion
linked
compositions
methods
Prior art date
Application number
BR112015022701A
Other languages
English (en)
Portuguese (pt)
Inventor
David Rubenstein
Kasper Runager
Original Assignee
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina Chapel Hill filed Critical Univ North Carolina Chapel Hill
Publication of BR112015022701A2 publication Critical patent/BR112015022701A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/01Hexosyltransferases (2.4.1)
    • C12Y204/01186Glycogenin glucosyltransferase (2.4.1.186)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/01Hexosyltransferases (2.4.1)
    • C12Y204/01255Protein O-GlcNAc transferase (2.4.1.255)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Power Engineering (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
BR112015022701A 2013-03-11 2014-03-11 composições e métodos para segmentação de n-acetilglicosamina transferase o-ligada e promoção da cicatrização de feridas. BR112015022701A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361775937P 2013-03-11 2013-03-11
PCT/US2014/023525 WO2014164805A1 (en) 2013-03-11 2014-03-11 Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing

Publications (1)

Publication Number Publication Date
BR112015022701A2 true BR112015022701A2 (pt) 2018-09-25

Family

ID=51658978

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022701A BR112015022701A2 (pt) 2013-03-11 2014-03-11 composições e métodos para segmentação de n-acetilglicosamina transferase o-ligada e promoção da cicatrização de feridas.

Country Status (13)

Country Link
US (1) US20170166897A1 (https=)
EP (1) EP2970978A4 (https=)
JP (1) JP2016513968A (https=)
KR (1) KR20150126048A (https=)
CN (1) CN105408480A (https=)
AU (1) AU2014248966A1 (https=)
BR (1) BR112015022701A2 (https=)
CA (1) CA2905337A1 (https=)
CL (1) CL2015002599A1 (https=)
MX (1) MX2015012124A (https=)
RU (1) RU2015138544A (https=)
SG (1) SG11201507211YA (https=)
WO (1) WO2014164805A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12146883B2 (en) * 2018-12-06 2024-11-19 Biocapital Holdings, Llc Glucose sensors and methods of use thereof
CN111234022B (zh) * 2019-12-16 2024-03-22 江苏省药物研究所有限公司 抗n-乙酰氨基葡萄糖转移酶修饰的蛋白质单克隆抗体及杂交瘤细胞株和其制备方法与应用
CN112707955B (zh) * 2020-12-21 2022-01-18 山东润德生物科技有限公司 提高N-乙酰氨基葡萄糖产量的RamAM转录因子突变体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
AU6942598A (en) * 1997-03-31 1998-10-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The O-linked glcnac transferase (ogt): cloning, molecular expression, and methods ofuse
EP1102786A4 (en) * 1998-08-03 2002-03-06 Univ East Carolina AGENT COMPRISING ANTISENSE OLIGONUCLEOTIDES WITH LOW ADENOSINE CONTENT, COMPOSITION, KIT AND TREATMENTS
EP2314321B1 (en) * 1999-01-27 2014-06-04 Coda Therapeutics, Inc. Formulations comprising antisense nucleotides to connexins
RU2442989C2 (ru) * 2005-12-22 2012-02-20 Й-Оил Миллс, Инц. СПОСОБ ОБНАРУЖЕНИЯ САХАРНЫХ ЦЕПЕЙ С GlcNAc, СИНТЕЗИРОВАННЫХ GnT-V
WO2010042228A2 (en) * 2008-10-10 2010-04-15 Cornell University Methods for predicting disease outcome in patients with colon cancer
US20120046186A1 (en) * 2010-08-20 2012-02-23 Pelham Robert J Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs
JP2012083193A (ja) * 2010-10-12 2012-04-26 Univ Of Tokyo ヒストンタンパク質のグリコシル化を検出するための方法、並びに当該方法に用いられる抗体

Also Published As

Publication number Publication date
CL2015002599A1 (es) 2016-08-26
KR20150126048A (ko) 2015-11-10
CN105408480A (zh) 2016-03-16
JP2016513968A (ja) 2016-05-19
SG11201507211YA (en) 2015-10-29
AU2014248966A1 (en) 2015-10-29
US20170166897A1 (en) 2017-06-15
EP2970978A4 (en) 2016-11-02
CA2905337A1 (en) 2014-10-09
RU2015138544A (ru) 2017-04-18
MX2015012124A (es) 2016-04-28
EP2970978A1 (en) 2016-01-20
WO2014164805A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
IL282202A (en) Compositions and methods for personalized neoplasia vaccines
FR21C1059I2 (fr) Compositions pharmaceutiques
IL267681B (en) Selective grp94 inhibitors and uses thereof
DK3290407T3 (da) Bromodomæneinhibitorer
PL2941442T3 (pl) Sposób wytwarzania mikrofibrylarnej celulozy
EP2961402A4 (en) BIOSYNTHESIS OF CANNABINOIDS
EP3566740C0 (en) FISTULAR FORMULATION/FORMATION DEVICES
PL3623002T3 (pl) Cewnik
HRP20180817T1 (hr) Sastavi i postupci za modulaciju farnesoid-x-receptora
HRP20180684T1 (hr) Kombinacija lijekova
EP3756591C0 (en) EMBOLIZATION SYSTEMS
PL3239134T3 (pl) Pirydonoamidy jako modulatory kanałów sodowych
EP2944924A4 (en) ABSOLUTELY MAGNETIC CODIER WITH MULTI-TURNING
DK3076983T3 (da) Ioniske vandige sammensætninger
EP2975063A4 (en) LOW SUBSTITUTED CELLULOSE ACETATE
EP2960538A4 (en) Magnetic brake
EP2972950A4 (en) SEGMENTATION OF A CONTENT
DK3003411T3 (da) Nedbrydelig hæmostat-komposition
DK3003412T3 (da) Nedbrydelig hæmostatsammensætning
DK3017139T3 (da) Undersøisk interventionssystem
DK3071053T3 (da) Præbiotisk sammensætning
EP2967936A4 (en) SUSPENDED STENT
EP2974162A4 (en) Non-retained message system
FR3005392B1 (fr) Composition anti-regurgitation preservant le transit intestinal
EP3017500C0 (en) RADAR SYSTEM

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.